Kornimate/medical-research-clean huggingface dataset:
nipple-sparing mastectomy in combined with buried flap monitoring

Conditions: Breast/Surgery

Summary: 1. learning curve of ms-tram and diep breast reconstructions surgery are important to guide the training of new surgeon. 2. buried flap post operative monitoring without implantable doppler was seldom studied, a validated protocol reported. 3. the complication rates of the flap and oncological safety were studied.

operative time and complication rate are employed to analysis the learning curve of the ms-tram and diep surgery,which is meaningful for the new microsurgeon training. buried flap without the implatable doppler is very common condition all over the world, and the complication rate was evaluated as evidence of reliable of the validated monitoring protocol. complication rates were considered as different before and after the platue of the learning curve. within the study of the learning curve, complication rates were reported.

Eligibility criteria:
inclusion criteria: * female breast cancer patients with age \> 18 years * received autologous abdominal free-flap breast reconstruction (including muscle-sparing free tram or diep) exclusion criteria: * breast conserving patient * implant-based breast reconstruction

Keywords: breast cancer diep ms-tram breast reconstruction learning curve nipple spring mastectomy
3 tesla (3t) stroke medical radiologic technology (mrt) for examining mismatch in 1000+

Conditions: Acute Stroke; Transient Ischemic Attack

Summary: the purpose of this study is to compare clinical and economic parameters of stroke patients who have received acute mri imaging (test group) to patients who have received routine ct imaging (control group) in the clinical setting of acute stroke.

the primary objective: * prospective validation of infarct development in ischemic stroke and transitory ischemic attacks on the basis of all patients given a preliminary diagnosis of stroke or tia in the emergency ward of the benjamin franklin campus of charité-universitätsmedizin berlin. secondary objectives: * determination of the spontaneous reperfusion rate in patients with an initial mismatch in the correlation between the time from onset of symptoms to the time of first imaging and nihss score severity * characterization of metabolic changes in ischemic tissue in cases of minor subcortical infarct using high resolution diffusion weighted mri (dwi) and perfusion mri with 2nd pass corrected cbf cards * proof of the principle that stroke mri can improve patient care / shorten the period in which patients are bedridden * measurement of the diffusion tensor in acute ischemic stroke (hamburg dti study) * proof of structural damage and investigation of pathogenesis in patients suffering from clinical transitory ischemic attacks (tia) * investigation of the correlation of clinical symptoms and lesion site as well as of changes in cortical plasticity in patients with solitary thalamus infarct * brain plasticity and motor learning in cases of a purely cortical infarct * characterization of gender specific damage patterns in stroke * morphologic and pathophysiological typing of the cryptic and cardial embolic infarct in correlation to incidence of arrhythmia * characterization of localization and morphology of infarcts in patients presenting in the emergency ward with central vestibular nerve syndrome / recording frequency of cerebral sessions in patients presenting with a primary diagnosis of central vestibular nerve lesion * clinical characterization of cerebellar and brain stem infarcts which are accompanied by vertigo symptoms and their correlation to infarct location

Eligibility criteria:
inclusion criteria: * suspected stroke or tia within 24 hours from symptom onset exclusion criteria: * mri contraindication

Keywords: acute (< 24 hours) stroke stroke tia mri imaging acute
treatment of locally advanced breast cancer with letrozole in postmenopausal women

Conditions: Locally Advanced Breast Cancer

Summary: open-label phase iv trial of letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( er and pr)


Eligibility criteria:
inclusion criteria: 1. postmenopausal women 2. primary locally invasive breast cancer 3. histological confirmed by core needle biopsy, whose tumors are estrogen (er) and / or progesterone (pgr) positive, defined by core biopsy immunohistochemistry with \> 10% positive malignant epithelial cells. 4. post menopausal status 5. tumor measurable by clinical examination, mammography and ultrasound exclusion criteria: 1. prior treatment with letrozole or tamoxifen. 2. patients with bilateral breast tumors 3. patients who are eligible for breast conserving surgery 4. evidence of inflammatory breast cancer or distant metastasis. 5. other concurrent malignant disease 6. concomitant anti-cancer treatments such as chemotherapy other protocol-defined exclusion criteria may apply.

Keywords: breast cancer, letrozole, hormonal receptors
outcomes following pre-marking of episiotomy location

Conditions: Episiotomy; Complications; Episiotomy Extended by Laceration; Episiotomy Infection

Summary: to compare short- and long-term outcomes of women following episiotomy during the second stage of labor, following marking of episiotomy location during the first stage of labor with those of women who underwent episiotomy without marking.

purpose: to compare short- and long-term outcomes of women following episiotomy during the second stage of labor, following marking of episiotomy location during the first stage of labor with those of women who underwent episiotomy without marking. hypothesis: women following episiotomy following pre-marking of the location will suffer from fewer short- and long-term complications compared to those without pre-marked episiotomy location. study type: prospective randomized-controlled trial

Eligibility criteria:
inclusion criteria: * women 18 years of age or older who present in active labour to our center and consent to participate in the study exclusion criteria: * women under 18 years of age or those who do not or are unable to provide informed consent to participate in the study

Keywords: episiotomy episiotomy complications premarked episiotomy
open-label study to evaluate the long-term safety and efficacy of vi-0521 in type 2 diabetic adults

Conditions: Diabetes

Summary: this study is an extension of a study that has been ongoing for 1 year. the purpose of this open label study is to see the how well type 2 diabetics respond to vi-0521(phentermine/topiramate) in controlling blood sugar and how safe vi-0521 is over an extended period of time. all subjects eligible to enroll into this study will receive study drug.


Eligibility criteria:
inclusion criteria: * have completed the qualifying dm-230 trial * if females of child-bearing potential, subjects must be using adequate contraception * provide written informed consent * be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures * be greater than 80% compliant in study medication use during the last three visits for dm-230 exclusion criteria: * subjects who have developed one or more morbidities during the dm-230 trial that would pose a safety concern

Keywords: diabetes type 2 diabetes diabetes mellitus metabolic diseases glucose metabolism disorders glycemic control
study of arthritis and related conditions

Conditions: Rheumatoid Arthritis

Summary: this research protocol will recruit patients with arthritis and related conditions for the purpose of screening patients for treatment protocols, and evaluating the natural history of arthritis and related conditions. patients will be evaluated clinically, radiographically and serologically, and standardized data will be uniformly collected on all patients. additional imaging using sensitive mri methods will be obtained in some patients. the collected blood and tissue will be utilized for laboratory studies to continue research on the pathogenic mechanisms of rheumatoid arthritis and related autoimmune joint diseases. data from the history and physical examination as well as several disability questionnaires in the adult and pediatric population will be used to phenotypically characterize these patients and assess outcome and functional status. any medical care recommended or provided to the patients will be consistent with routine standards of practice and provided in consultation with the patient's referring physician.

this research protocol will recruit patients with arthritis and related conditions for the purpose of screening patients for treatment protocols, and evaluating the natural history of arthritis and related conditions. patients will be evaluated clinically, radiographically and serologically, and standardized data will be uniformly collected on all patients. additional imaging using sensitive mri methods will be obtained in some patients. the collected blood and tissue will be utilized for laboratory studies to continue research on the pathogenic mechanisms of rheumatoid arthritis and related autoimmune joint diseases. data from the history and physical examination as well as several disability questionnaires in the adult and pediatric population will be used to phenotypically characterize these patients and assess outcome and functional status. any medical care recommended or provided to the patients will be consistent with routine standards of practice and provided in consultation with the patient's referring physician.

Eligibility criteria:
* inclusion criteria: no age limits. history of inflammatory synovitis of at least one or more swollen joints. patient's ability and willingness to give informed consent or in the pediatric patients, the parent's willingness to give informed consent and the patient's willingness to assent to the protocol whenever possible. exclusion criteria: none if patients fulfill inclusion criteria.

Keywords: pathogenesis
3,4-diaminopyridine for lambert-eaton myasthenic syndrome (lems) and congenital myasthenia (cm)

Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS); Congenital Myasthenia (CM)

Summary: lambert-eaton myasthenic syndrome (lems) is a rare autoimmune disorder which affects the nerve-muscle junction. the major symptoms of lems are progressive muscle weakness. many patients experience other symptoms like dry mouth or impotence. congenital myasthenia (cm) is an inherited disorder with similar affects and symptoms. 3,4-diaminopyridine (dap) is an experimental drug that has improved strength in some subjects with (lems). there are no other accepted treatments for lems and dap has relatively few side effects.

subjects with clinically confirmed lems or cm will receive 3,4-diaminopyridine (3,4 dap) by mouth in slowly increasing doses. treatment will begin with 5-10 mg three times a day. a common final dosage is 15-20 mg four or five times a day, as clinically needed, and if tolerated. the upper limit is a total of 100 mg/day. subjects will be monitored for strength and side effects via routine clinic visits at intervals of one month for the first three months, then every three months for the first year, and at least every six months thereafter. treatment will be continued indefinitely if a good clinical response is achieved and side effects are tolerable.

Eligibility criteria:
inclusion criteria: * diagnosis of lems or cm * if female and over the age of 9, must have a negative pregnancy test, and, if premenopausal, must be willing to practice an effective form of birth control. * must be tested and found by ecg not to have a prolonged q-tc syndrome. * must agree to have a second ecg at the time of peak drug effect. exclusion criteria: * known to have sensitivity to 3,4-dap * history of clinical seizures or evidence of seizure activity on screening eeg * history of severe asthma

Keywords: 3,4dap, lems, cm
systematic review and meta-analysis of multaq® for safety in atrial fibrillation

Conditions: Atrial Fibrillation

Summary: a systematic literature review (slr) will be conducted to understand the landscape of evidence on the relative safety and effectiveness/efficacy of dronedarone compared to sotalol in patients with afib within interventional clinical trials and observational studies.


Eligibility criteria:
inclusion criteria: following eligibility criteria are defined to select relevant studies from the literature * adults with atrial fibrillation(afib) (non-permanent, including paroxysmal or persistent, long-standing persistent afib \[over 12 months\])) * participants have received either dronedarone or sotalol * controlled clinical trials or comparative observational studies( prospective/retrospective cohort, case-control studies, population-based studies or registry based studies exclusion criteria: exclusion criteria for potential participants are: * children/adolescents * permanent atrial fibrillation (afib)
natural history of amyloid deposition in adults with down syndrome

Conditions: Down Syndrome

Summary: the primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with ds as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups. we will also obtain baseline cognitive measures across a range of areas that are often affected by ad.

specific aim 1: to assess and compare amyloid deposition (with pib pet) in non-demented/functionally stable adults with ds across three age cohorts (30-39, 40-49, and \>50 years of age). primary hypothesis 1: at initial assessment, there will be a significantly higher prevalence of amyloid-positive (pib+) subjects in each succeeding age cohort. in addition, we will test the following secondary hypothesis: secondary aim 1: to compare the presence or absence of the apolipoprotein-e4 allele to the retention of pib in various brain areas of the ds subjects. secondary hypothesis 1: at baseline, subjects who carry at least one apolipoprotein-e4 (apoe4) allele will show a higher prevalence of being pib+.

Eligibility criteria:
inclusion criteria: 1. participant iq at least 47 (based upon stanford-binet v abbrev. test battery) 2. participant at least 30 years of age 3. dsds score indicating participant is asymptomatic for ad 4. reliable caregiver who is capable of providing correct information about the participant's clinical symptoms and history 5. agreement of caregiver and clinician that participant is able to cooperate with the protocol tasks 6. participant has provided assent (or consent) and/or parent/caregiver has provided informed consent exclusion criteria: 1. participant is non-verbal or has extremely limited language skills 2. score within the "symptomatic" range on the dsds 3. any significant disease or unstable medical condition that could affect neuropsychological testing 4. any problems with vision or hearing that could affect neuropsychological testing 5. participants in whom mri is contraindicated 6. claustrophobia or prior failed experiences of completing mri scans or blood draws 7. participant is pregnant or breast feeding 8. history or other evidence of severe illness or other condition that would make the participant, in the opinion of the investigator, unsuitable for the study?

Keywords: beta amyloid, down syndrome, alzheimer's disease
study of mindfulness-based cognitive therapy

Conditions: Major Depressive Disorder

Summary: research aimed at assessing changes in depressogenic thinking and the ability to disengage from depressogenic thinking following mindfulness-based cognitive therapy


Eligibility criteria:
inclusion criteria: * history of two or more major depressive episodes or history of a major depressive episode lasting at least one year * can speak, read, and understand english exclusion criteria: * meet criteria for current major depressive episode or are in partial remission * bdi-ii score above 19 * abuse alcohol or drugs * current dysthymic disorder * history of: psychosis when not depressed or intoxicated, mania, hypomania, obsessive compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa

Keywords: mbct mindfulness-based cognitive therapy mindfulness meditation relapse prevention recurrent depression depression major depressive disorder
association of tnfaip3 with immune-mediated ttp

Conditions: Thrombotic Thrombocytopenic Purpura, Acquired

Summary: this study aims to investigate whether genetic variation in the tnfaip3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (ittp), and whether such association is mediated by decreased expression of a20 (tnfaip3). the study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.


Eligibility criteria:
patients: inclusion criteria: * diagnosis of ittp * above 12 years of age * caucasian, italian origin * written informed consent to participate in the study exclusion criteria: * patients who do not meet the above-listed criteria will be excluded from participation in the study. controls will be healthy italian volunteers of caucasian ethnicity, with no history of thrombotic thrombocytopenic purpura, frequency-matched to cases by age and sex, and who have provided written informed consent to participate in the study.

Keywords: a20 ittp tnfaip3
effects of preoperative coffee consumption in cesarean sections under spinal anesthesia

Conditions: Hypotension After Spinal Anesthesia; Post-Dural Puncture Headache

Summary: the prospective study is planned in a university hospital. spinal anesthesia is widely used for cesarean section currently for its safety, low cost, reliability, easiness to administer, immediate effect, and well-operating conditions. however spinal anesthesia has some complications as hypotension, bradycardia and post dural puncture headache (pdph). a practical strategy for avoiding hypotension during initiation of spinal anesthesia for cesarean delivery includes intravenous crystalloid, in conjunction with administration of vasopressors. pdph is one of the most frequent complications of spinal anesthesia. conservative therapies such as bed rest, hydration, and caffeine are commonly used as management. for this study, coffee group of patients will be given unsweetened brewed coffee 150 ml until 2-4 hours before surgery. patients who accept to drink brewed coffee ( coffee group) and water( control group) will be included in the study. the patient's heart rate, blood pressure, oxygen saturation will be monitored and recorded during operation. intraoperative will be recorded to amount of vasopressor and intraveous crystalloid. whether the patient develops pdph in the postoperative period will be followed for 3 days. in addition abdominal auscultation for bowel sounds hourly and the time of first bowel movements will be recorded. according to the patient's statement, the time of first flatulence and defecation will be followed and recorded.


Eligibility criteria:
inclusion criteria: * patients who accept to participate in the study * patient who limit the consumption of caffeinated beverages such as coffee and tea during pregnancy * patients with known caffeine or coffee allergy exclusion criteria: * patients who refuse to participate in the study * patients with known cardiovascular disease * patients with known cerebrovascular disease * patients with known neurological, neurodegenerative or psychiatric disease * patients with known liver failure * patient followed up with eclampsia and preaclampsi * higher number of needle passes in spinal anesthesia * patients treated with an antiemetic
effect of beetroot juice on coronary blood flow and walking performance in pad

Conditions: Peripheral Arterial Disease

Summary: in this study the investigators will test the hypothesis that short-term consumption of inorganic nitrate (supplied in concentrated beetroot juice) enhances coronary blood flow responses, large artery hemodynamics, and leg oxygenation/exercise tolerance in patients with peripheral arterial disease (pad). understanding and improving blood flow regulation in the heart and skeletal muscles of patients with pad is important because exercise triggers symptoms of leg pain and substantially raises blood pressure and myocardial demand in these patients.

peripheral arterial disease (pad) is a strong predictor of cardiovascular mortality and negatively affects functional capacity and quality of life for as many as 14 million patients in the u.s. alone. one open-label study showed that acute consumption of beetroot juice improved 6 min walk performance, reduced blood pressure, and enhanced leg muscle oxygenation in pad patients. however, no studies have rigorously confirmed these findings in a double-blind manner, nor have the effects of this supplement been investigated (acutely or short-term) in the coronary circulation of pad patients. in addition to studying its effects on graded treadmill walking performance and consequent large artery vasodilation, the present study will examine the effects of short-term beetroot juice consumption (twice/day) on both coronary and leg vasodilator (graded calf flexion) and vasoconstrictor (isometric handgrip, voluntary apnea) responses in patients with pad. participants will randomly consume either nitrate-rich or nitrate-depleted beetroot juice with a 7 to 14 day wash-out period between. effects of beetroot juice consumption on plasma nitrate, nitrite and methemoglobin will also be assessed.

Eligibility criteria:
inclusion criteria: 1. patients with peripheral arterial disease (pad) 2. capable of giving informed consent 3. men and women age 21- 85 years 4. diagnosed with pad (i.e., ankle-brachial index below 0.9) 5. fontaine stage ii or less - no pain while resting 6. satisfactory history and physical exam exclusion criteria: 1. children 2. pregnant or nursing women 3. patients taking nitroglycerine or nitrate preparations 4. patients taking phosphodiesterase inhibitors such as sildenafil or tadalafil 5. patients taking proton pump inhibitors 6. ejection fraction \< 40% 7. uncontrolled hypertension 8. uncontrolled diabetes 9. myocardial infarction within past 6 months or unstable angina 10. severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers) 11. abnormality in hemoglobin or hematocrit or methemoglobin 12. impaired renal function 13. impaired liver function 14. history or diagnosis of barrett's esophagus 15. known allergy to beetroot juice or lemon juice 16. inability to walk on a treadmill at a moderate pace (2.0 miles/hour)

Keywords: dietary nitrate supplementation beetroot juice